Touloumi G - Search Results

1

Boosted lopinavir- versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: a prospective study of HIV-infected individuals in high-income countries.

HIV-CAUSAL Collaboration; Cain LE, Phillips A, Olson A, Sabin C, Jose S, Justice A, Tate J, Logan R, Robins JM, Sterne JA, van Sighem A, Reiss P, Young J, Fehr J, Touloumi G, Paparizos V, Esteve A, Casabona J, Monge S, Moreno S, Seng R, Meyer L, Pérez-Hoyos S, Muga R, Dabis F, Vandenhende MA, Abgrall S, Costagliola D, Hernán MA. HIV-CAUSAL Collaboration, et al. Among authors: touloumi g. Clin Infect Dis. 2015 Apr 15;60(8):1262-8. doi: 10.1093/cid/ciu1167. Epub 2015 Jan 6. Clin Infect Dis. 2015. PMID: 25567330 Free PMC article.

2

Estimation and comparison of rates of change in longitudinal studies with informative drop-outs.

Touloumi G, Pocock SJ, Babiker AG, Darbyshire JH. Touloumi G, et al. Stat Med. 1999 May 30;18(10):1215-33. doi: 10.1002/(sici)1097-0258(19990530)18:10<1215::aid-sim118>3.0.co;2-6. Stat Med. 1999. PMID: 10363341

3

Virological and immunological response to HAART therapy in a community-based cohort of HIV-1-positive individuals.

Touloumi G, Paparizos V, Sambatakou H, Katsarou O, Chrysos G, Kordossis T, Antoniadou A, Hatzitheodorou H, Stavrianeas N, Gargalianos P, Karafoulidou A, Lazanas M, Giamarelou H, Hatzakis A. Touloumi G, et al. HIV Clin Trials. 2001 Jan-Feb;2(1):6-16. doi: 10.1310/YN11-XJ4L-9YHF-19E4. HIV Clin Trials. 2001. PMID: 11590509 Clinical Trial.

4

Impact of missing data due to drop-outs on estimators for rates of change in longitudinal studies: a simulation study.

Touloumi G, Babiker AG, Pocock SJ, Darbyshire JH. Touloumi G, et al. Stat Med. 2001 Dec 30;20(24):3715-28. doi: 10.1002/sim.1114. Stat Med. 2001. PMID: 11782028

5

Impact of missing data due to selective dropouts in cohort studies and clinical trials.

Touloumi G, Pocock SJ, Babiker AG, Darbyshire JH. Touloumi G, et al. Epidemiology. 2002 May;13(3):347-55. doi: 10.1097/00001648-200205000-00017. Epidemiology. 2002. PMID: 11964938

6

Significance of immune status, genotype and viral load in the severity of chronic hepatitis C in HIV infected haemophilia patients.

Delladetsima J, Katsarou O, Touloumi G, Vgenopoulou S, Hatzakis A, Karafoulidou A. Delladetsima J, et al. Among authors: touloumi g. Haemophilia. 2002 Sep;8(5):668-73. doi: 10.1046/j.1365-2516.2002.00670.x. Haemophilia. 2002. PMID: 12199677

7

Changes over calendar time in the risk of specific first AIDS-defining events following HIV seroconversion, adjusting for competing risks.

Babiker A, Darbyshire J, Pezzotti P, Porter K, Rezza G, Walker SA, Beral V, Coutinho R, Del Amo J, Gill N, Lee C, Meyer L, Tyrer F, Dabis F, Thiebaut R, Lawson-Aye S, Boufassa F, Hamouda O, Fischer K, Pezzotti P, Rezza G, Touloumi G, Hatzakis A, Karafoulidou A, Katsarou O, Brettle R, del Romero J, Prins M, van Benthem B, Kirk O, Pederson C, Hernández Aguado I, Pérez-Hoyos S, Eskild A, Bruun JN, Sannes M, Sabin C, Lee C, Johnson AM, Phillips AN, Francioli P, Vanhems P, Egger M, Rickenbach M, Cooper D, Kaldor J, Ashton L, Vizzard J, Muga R, Day NE, De Angelis D; CASCADE Collaboration. Babiker A, et al. Among authors: touloumi g. Int J Epidemiol. 2002 Oct;31(5):951-8. doi: 10.1093/ije/31.5.951. Int J Epidemiol. 2002. PMID: 12435766 Free PMC article.

8

Elevated serum levels of soluble immune activation markers are associated with increased risk for death in HAART-naive HIV-1-infected patients.

Sipsas NV, Sfikakis PP, Touloumi G, Pantazis N, Choremi H, Kordossis T. Sipsas NV, et al. Among authors: touloumi g. AIDS Patient Care STDS. 2003 Apr;17(4):147-53. doi: 10.1089/108729103321619755. AIDS Patient Care STDS. 2003. PMID: 12737638 Clinical Trial.

9

Changes in T cell receptor excision DNA circle (TREC) levels in HIV type 1-infected subjects pre- and post-highly active antiretroviral therapy.

Touloumi G, Pantazis N, Karafoulidou A, Mandalaki T, Goedert JJ, Kostrikis LG, Hatzakis A. Touloumi G, et al. AIDS Res Hum Retroviruses. 2004 Jan;20(1):47-54. doi: 10.1089/088922204322749495. AIDS Res Hum Retroviruses. 2004. PMID: 15000698 Clinical Trial.

10

Differences in HIV RNA levels before the initiation of antiretroviral therapy among 1864 individuals with known HIV-1 seroconversion dates.

Touloumi G, Pantazis N, Babiker AG, Walker SA, Katsarou O, Karafoulidou A, Hatzakis A, Porter K; CASCADE Collaboration. Touloumi G, et al. AIDS. 2004 Aug 20;18(12):1697-705. doi: 10.1097/01.aids.0000131395.14339.f5. AIDS. 2004. PMID: 15280781

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

274 results

Search Page